유럽 연합 - 슬로바키아어 - EMA (European Medicines Agency)

janssen-cilag international nv - guselkumab - svrab - imunosupresíva - plaque psoriasis tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritis tremfya, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (dmard) therapy (see section 5.

유럽 연합 - 슬로바키아어 - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - spesolimab - svrab - imunosupresíva - spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (gpp) as monotherapy.